Skip to main content Skip to main navigation menu Skip to site footer

Progressive ovarian sertoli – leydig cell tumor: case report

  • Juanda Raynaldi ,
  • Hasanuddin ,
  • Sarah Ika Nainggolan ,
  • Munizar ,


Introduction: Ovarian Sertoli – Leydig Cell Tumor (SLCT) are one of sex cord tumor that has incidence rate less than 0,2% of all ovarian tumors. It occurs predominantly in second and third decades of lifetime. It has characteristics mostly low–grade malignant although poorly differentiated type may behave more aggressively. Clinical characterstic of ovarian SLCT usually hormonal changes, nevertheless in patients without hormonal changes, the manifestation of the disease consists of abdominal pain and abdominal enlargement, and palpable adnexal mass on physical diagnostic.

Case: a 52 years woman that has been undergo right salpingooforectomy 5 months prior with PA result shows poorly differentiated sertoli – leydig cell tumor, and refusing to chemotherapy. She came with chief complaint of abdominal enlargement since 3 months accompanied with lower abdominal pain 2 weeks prior. Ultrasound examination shows cystic ovarian neoplasm with solid part size 9 x 9 x 9 cm from left adnexa. Tumor markers that arise are Alpha–Fetoprotein (AFP)  52 ng/mL and Lactate Dehydrogenase (LDH) = 432 U/mL which correspond to sex cord tumor. She has undergone Laparotomy Total Abdominal Hysterectomy Left Salpingooforectomy and chemotherapy afterward.

Conclusion: Ovarian Sertoli – Leydig Cell Tumors (SLCT) are a rare sex cord ovarian tumor that may behave more aggressively as it poorly differentiated. It has manifestations of hormonal changes and also abdominal enlargement.


  1. Al Harbi R, McNeish IA, El-Bahrawy M. Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. Int J Gynecol Cancer. 2021;31(2):161–8.
  2. Durmuş Y, Kılıç Ç, Çakır C, Yüksel D, Boran N, Karalök A, et al. Sertoli–Leydig cell tumor of the ovary: Analysis of a single institution database and review of the literature. J Obstet Gynaecol Res. 2019;45(7):1311–8.
  3. Xu Q, Zou Y, Zhang XF. Sertoli-Leydig cell tumors of ovary: A case series. Medicine (Baltimore). 2018;97(42):e12865–e12865.
  4. de Kock L, Terzic T, McCluggage WG, Stewart CJR, Shaw P, Foulkes WD, et al. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. Am J Surg Pathol. 2017;41(9):1178–87.
  5. De Paolis E, Paragliola RM, Concolino P. Spectrum of DICER1 Germline Pathogenic Variants in Ovarian Sertoli-Leydig Cell Tumor. J Clin Med. 2021;10(9):1845.
  6. Lim D, Oliva E. Ovarian sex cord-stromal tumours: an update in recent molecular advances. Pathology. 2018;50(2):178–89.
  7. Gouy S, Arfi A, Maulard A, Pautier P, Bentivegna E, Leary A, et al. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors. Oncologist. 2018/09/10. 2019;24(5):702–9.
  8. Castro BGR, Souza C de P, Andrade CEM da C, Vieira M de A, Andrade DAP de, Reis R dos. Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors. Rev Bras Ginecol e Obs / RBGO Gynecol Obstet. 2019;41(07):440–8.
  9. Yuan Z, Huo X, Jiang D, Yu M, Cao D, Wu H, et al. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors. Oncologist. 2020;25(9):e1396–405.
  10. Melero Cortés LM, Martínez Maestre MÁ, Vieites Pérez-Quintela MB, Gambadauro P. Ovarian Sertoli–Leydig cell tumours: How typical is their typical presentation?. J Obstet Gynaecol (Lahore). 2017;37(5):655–9.

How to Cite

Raynaldi, J., Hasanuddin, Nainggolan, S. I. ., & Munizar. (2023). Progressive ovarian sertoli – leydig cell tumor: case report. Bali Medical Journal, 12(2), 1394–1396.